Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Benzene ring nonionically bonded

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514553000 - Radical -XH acid, or anhydride, acid halide or salt thereof (X is chalcogen) DOAI

514557000 - Carboxylic acid, percarboxylic acid, or salt thereof (e.g., peracetic acid, etc.)

514561000 - Nitrogen other than as nitro or nitroso nonionically bonded

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20100087537REDUCED IRRITANT ENEMA FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE (IBD) - The present invention comprises packaged enemas for the treatment of Inflammatory Bowel Disease (IBD), having substantially pure 5-ASA as the active ingredient, with a liquid carrier medium having a material avoidance of bowel irritant substances, such as anti-oxidants for the 5-ASA active ingredient, including such sulfites as potassium metabisulfite, for example, and contained within a sealed and substantially oxygen-free barrier package, which may preferably be formed of a foil/polymer laminate, and which package contains or otherwise includes an oxygen scavenger, such as a an oxygen scavenging sachet.04-08-2010
20090312424AROMATIC PRODRUGS OF PROPOFOL, COMPOSITIONS AND USES THEREOF - Prodrugs of propofol, methods of making prodrugs of propofol, pharmaceutical compositions of prodrugs of propofol and methods of using prodrugs of propofol and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as migraine headache pain and post-chemotherapy or post-operative surgery nausea and vomiting are disclosed herein.12-17-2009
20130041034Treatment of pain with topical diclofenac compounds - The field involves compositions useful for pain relief, including diclofenac solution and gel formulations, in particular methods of use thereof, articles of manufacture and kits that provide novel preclinical, clinical and other information to users.02-14-2013
20100099767Topical Pharmaceutical Formulation - A composition for topical application of an NSAID comprises a solution or suspension of the NSAID in a carrier system comprising a polyhydric alcohol, a glycol ether and an ester of A higher fatty acid, the carrier system being present as a single phase at ambient temperatures. The NSAID may be diclofenac as diclofenac acid. The polyhydric alcohol may be a glycol such as isopropylene glycol and the glycol ether may be a diethylene glycol ether such as diethylene glycol monoethyl ether.04-22-2010
20100029770Methods of treating mental retardation, down's syndrome, fragile X syndrome and autism - Subjects having at least one condition selected from the group consisting of mental retardation, Down's syndrome, fragile X syndrome and autism are treated with a composition that includes gamma-aminobutyric acid agonists and/or M1 muscarinic receptor antagonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen. GABA(B) agonists can be used in combination with Group I mGluR antagonists and M1 muscarinic receptor antagonists in methods of treating humans.02-04-2010
20090042989NSAID FORMULATIONS, BASED ON HIGHLY ADAPTABLE AGGREGATES, FOR IMPROVED TRANSPORT THROUGH BARRIERS AND TOPICAL DRUG DELIVERY - The invention describes novel formulations of nonsteroidal anti-inflammatory drugs (NSAIDS) based on complex aggregates with at least three amphipatic components suspended in a suitable, e.g. pharmaceutically acceptable, polar liquid medium. A suitably ionised NSAID is one of the two, amongst said three, components that tends to destabilise lipid membranes, the other system component with such activity being typically a surfactant. In contrast, the remaining amongst said at least three amphipatic components typically forms a stable lipid membrane on it's own. An essential characteristics of the resulting, relatively large, aggregates is an improved ability to penetrate pores, in a semi-permeable barrier, at least 30%, and often much smaller than the average diameter of the complex aggregate. This enables said aggregates to mediate NSAID transport through semi-permeable barriers including mammalian skin. As a result of the skin penetration by NSAID loaded large aggregates, the drug delivered transcutaneously with such carriers gets deeper into the tissue than the corresponding NSAID from a solution on the skin surface. This is believed to be due to the special ability of suitable large carriers to bypass the local sink of blood capillaries at the epidermal-dermal junction in the skin. The carrier-mediated delivery of locally applied NSAIDs thus allows therapy of deep tissues under the drug administration site, which is medically highly desirable.02-12-2009
20130090384AQUEOUS LIQUID PREPARATION CONTAINING 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID - An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).04-11-2013
20130059915TREATMENT OF PAIN WITH TOPICAL DICLOFENAC - The field involves compositions useful for pain relief, including diclofenac solution and gel formulations, in particular methods of use thereof, articles of manufacture and kits that provide novel preclinical, clinical and other information to users.03-07-2013
20110015270Novel NIDDM Regimen - The present invention relates to the use of a short-acting oral hypoglycemic agent and to a novel regimen in the treatment of type 2 diabetes in which the endogenous secretion of insulin is stimulated in connection with meals by administering in connection with the meals a short-acting oral hypoglycaemic agent. Also, the present invention relates to a method of achieving significantly improvement in the glycaemic control by a combined use of repaglinide and metformin in NIDDM patients poorly controlled on metformin alone.01-20-2011
20120190748GREATER UTILITY WITH THYROID HORMONE - Formulations and delivery systems that include a thyroid hormone active agent consisting essentially of T4 should reduce fluctuations in delivery of thyroid hormone.07-26-2012
20090298944PHARMACEUTICAL COMPOSITION - The present invention relates to a pharmaceutical composition of practically water insoluble or low water soluble compounds containing catechol moiety by enhancing the solubility of such compounds using one or more alkalising agent and optionally adding one or more pharmaceutically acceptable excipient. The present invention also relates to a process for preparing such pharmaceutical composition12-03-2009
20090270507Concentrated Liquid Thyroid Hormone Composition - This invention is directed generally to a liquid pharmaceutical composition comprising at least one thyroid hormone (particularly a composition further comprising at least one cyclodextrin compound), a process for making such a composition and a method of using such a composition to treat a condition associated with impaired thyroid hormone function.10-29-2009
20090270506CRYSTALLINE STRUCTURE OF OXIDOSQUALENE SYNTHASE - The present invention relates to crystal forms of mammalian OSC and the crystal structure information obtained from them, to methods of preparing such crystal forms, and to their use for the identification and/or design of inhibitors of OSC activity. A further subject matter of the invention are methods for the identification and/or design of inhibitor compounds of OSC activity, the inhibitor compounds of OSC activity identified by these methods and their use in pharmaceutical compositions for the treatment and/or prevention of diseases which are associated with OSC comprising hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasite infections and gallstones, and/or treatment and/or prophylaxis of impaired glucose tolerance, diabetes, tumors and/or hyperproliferative disorders, preferably for the treatment and/or prophylaxis of hypercholesterolemia and/or hyperlipemia.10-29-2009
20130065962Compounds For Use In The Treatment Of Diseases - The present invention relates to a compound of the general formula (III):03-14-2013
20090234012ADMINISTRATION OF DOPA PRECURSORS WITH SOURCES OF DOPA TO EFFECTUATE OPTIMAL CATECHOLAMINE NEUROTRANSMITTER OUTCOMES - A method of treating neurotransmitter dysfunction in a patient by optimizing catecholamine levels by administration of L-3,4-dihydroxyphenylalanine (L-Dopa or Dopa) precursors in combination with a source of L-Dopa. The dopa precursor is preferably administered in such quantities such that the amount of dopa from the dopa precursors does not fluctuate and affect outcomes in the synthesis of dopamine from dopa administration. The dopa precursor source is preferably tyrosine, but may alternatively be phenylalanine, N-acetyl-tyrosine, any active isomer thereof, or any other dopa precursor. The source of L-Dopa may include any natural or synthetic source, including, but not limited to, Mucuna pruriens.09-17-2009
20090012170TREATMENT OF SYMPTOMS OF MOTOR DYSFUNCTION - The present invention relates to the use of a COMT inhibitor in combination with a dopamine precursor and a peripheral decarboxylase inhibitor in the treatment of motor dysfunctions.01-08-2009
20100087536AMINO ACID DERIVED PRODRUGS OF PROPOFOL, COMPOSITIONS, USES AND CRYSTALLINE FORMS THEREOF - The present invention provides a prodrug of propofol and crystalline forms thereof, methods of making the propofol prodrug and crystalline forms thereof, pharmaceutical compositions of the propofol prodrug and crystalline forms thereof, methods of using the propofol prodrug and crystalline forms thereof and pharmaceutical compositions thereof to treat diseases or disorders such as headache pain, post-chemotherapy or post-operative surgery nausea and vomiting, neurodegenerative disorders, and mood disorders.04-08-2010
20090197960Method of Inhibiting Polyneuropathic Pain with 3-(2-Dimethylaminomethylcyclohexyl) Phenol - A method of using 3-(2-dimethylaminomethylcyclohexyl)phenol or a pharmaceutically acceptable salt thereof as an active pharmaceutical ingredient for treating or inhibiting polyneuropathic pain, in particular in diabetic polyneuropathy.08-06-2009
20110136911TREATMENT OF SEPSIS AND INHIBITION OF MIF BY D-T4 - Methods and compositions are disclosed for the use of dextrothyroxine (D-T4) to treat sepsis, inflammation, and conditions and diseases in which it is desirable to inhibit macrophage migration inhibitory factor (MIF).06-09-2011
20120289602PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING BURN INJURIES - The present invention relates to a pharmaceutical composition and the method of use for treating or preventing burn injury in patients or subjects in need, including the compound represented by the specific chemical formula as an active ingredient or its pharmaceutically acceptable salts or solvates.11-15-2012
20100190859Citrate Salt of Rasagiline - The subject invention provides rasagiline citrate, its compositions and processes for the manufacture thereof.07-29-2010
20110281947METHODS OF ADMINISTERING DICLOFENAC COMPOSITIONS FOR TREATING PHOTODAMAGED SKIN - A method of treating at least one dermatological disorder selected from the group consisting of photodamage-induced wrinkles, rosacea, and acne, includes: (a) providing a composition containing 1-3 wt. % diclofenac or a salt thereof, 0.5-1.5 wt. % benzyl alcohol; 10-30 wt. % PEG monomethyl ether, 0.1-3.0 wt. % sodium hyaluronate; and 70-80 wt. % water; and (b) applying the composition to skin of a person in need of the treating in an amount effective to treat the at least one dermatological disorder.11-17-2011
20110288174Monohydrate of 4-(phenyl)ethyl]-amino}methyl)benzoic acid - The invention relates to novel forms of 4-({(4-carboxybutyl) [2-(2-{[4-(2-phenylethyl)benzyl]oxy}phenyl)ethyl]amino}methyl)benzoic acid, in particular to the monohydrate in form A, to processes for their preparation, to medicaments comprising them and to their use for fighting diseases.11-24-2011
20120004305EXTERNAL PREPARATION CONTAINING ANALGESIC/ANTI-INFLAMMATORY AGENT - An external preparation containing the following components (A), (B), (C), and (D): 01-05-2012
20110294889Infusion and Injection Solution of Levodopa - An infusion or injection solution of Levodopa containing at least 10 mg/mL of Levodopa, or at least 5 mg/mL of Levodopa together with at least 0.5 mg/mL of at least one inhibitor of a Levodopa-metabolising enzyme is disclosed. The solution further contains a buffer, a physiologically acceptable sugar, such as glucose, a physiologically acceptable acid, such as hydrochloric acid, and optionally a stabilizer, and has a pH of lower than or equal to 6. There are also described a disposable syringe containing an infusion or injection solution of Levodopa, optionally together with a Levodopa-metabolising enzyme, and an infusion pump cassette containing an infusion or injection solution of Levodopa optionally together with a Levodopa-metabolising enzyme.12-01-2011
20110201684EP2 Agonist from Non-Prostanoid Structures Designed as PGE2 Antagonists - A method of treating ocular hypertension, lowering intraocular pressure, pain or inflammation, comprising administering to a mammal a pharmaceutical composition of an EP08-18-2011
20090149542COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION - The present invention relates to 2-hydroxy-alkylamino-benzoic acid derivatives and to a combination of cell necrosis inhibitor and lithium, process for the preparation of the derivatives or the combination, pharmaceutical formulation containing the derivatives or the combination, and use of the derivatives or the combination by either concomitant or sequential administration for improvement of treatment of neuronal death or neurological dysfunction. The derivatives and the combination of the present invention are useful for treating neurological diseases, such as amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), spinal muscular atrophy, Alzheimer's disease, Parkinson's disease, Huntington's disease, stroke, traumatic brain injury or spinal cord injury; and for treating ocular diseases such as glaucoma, diabetic retinopathy or macular degeneration.06-11-2009
20120035265COMPOSITIONS, METHODS, AND DEVICES FOR THE TREATMENT OF DYSMENORRHEA - A method for a prevention and/or treatment of dysmenorrhea or amelioration of a symptom thereof in a subject, comprising administering to said subject an effective amount of a compound of formula I:02-09-2012
20090082452DEUTERIUM-ENRICHED LUMIRACOXIB - The present application describes deuterium-enriched lumiracoxib, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-26-2009
20090221707Process for preparing a pharmaceutical composition with anti-inflammatory and analgesic activity for administration via a patch for external use, and composition thus obtained - The present invention relates to a process for preparing a pharmaceutical composition with anti-inflammatory and analgesic activity for administration via a patch for external use, its components including as active principle a salt of diclofenac, 2[(2,6-dichlorophenyl)amino]benzene-acetic acid, with a cyclic organic base chosen from hydroxyethylpyrrolidine or hydroxyethylpiperidine characterized in that said active principle is added to a mixture of one or more of said components, in the form of a solution in water and propylene glycol in a ratio of about 1:1 parts by weight.09-03-2009
20080287543Pharmaceutical composition comprising 5-methyl-2 (2'-chloro-6'-fluoroanillino) phen ylacetic acid - The invention relates to a composition for the treatment of a cyclooxygenase-2-mediated disorder or condition comprising 5-methyl-2-(2′-chloro-6′-fluoroanilino)phenylacetic acid or a pharmaceutically acceptable salt, preferably the potassium salt, thereof suitable for parenteral administration, and to a method for the treatment of a cyclooxygenase-2-mediated disorder or condition in a human or animal in need of such treatment by parenteral administration of 5-methyl-2-(2′-chloro-6′-fluroanilino)phenylacetic acid or a pharmaceutically acceptable salt, preferably the potassium salt, thereof.11-20-2008
20100099766Topical NSAID compositions having sensate component - Topical analgesic compositions comprising a topically administrable NSAID, a sensate agent and optionally a self-warming system, when administered to a patient in need thereof, provide significant improvements in the rate and extent of skin absorption, as well as impart a sensation of rapid and complete relief from pain.04-22-2010
20090292023Method of Treating Post-Surgical Acute Pain - A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than or equal to about 100 mg. The method is particularly useful in treating acute pain in bunionectomy patients.11-26-2009
20090292022Method of Treating Post-Surgical Acute Pain - A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than or equal to about 100 mg. The method is particularly useful in treating acute pain in bunionectomy patients.11-26-2009
20080306160Preventive or therapeutic agent for disease caused by decrease in lacrimal fluid - The present invention provides pharmaceuticals for the prevention or treatment of diseases associated with decrease in tear. That is, the present invention provides pharmaceuticals for the prevention or treatment of diseases associated with decrease in tear such as dry eye, dry disorders of cornea and conjunctiva, disorders of the keratoconjunctival epithelium, syndrome with decrease in tear secretion, xerophthalmia, dry eye due to aging, opthalmopathy in Stevens-Johnson syndrome, opthalmopathy in Sjögren's syndrome, keratoconjunctival ulcer, dryness in wearing of contact lens or the like, which comprises a β12-11-2008
20080293814CONCENTRATE ESMOLOL - A concentrate esmolol formulation is provided that is safer than current concentrate (e.g., 250 mg/ml) esmolol compositions. The concentrate esmolol formulation can include from about 40-60 mg/ml of esmolol hydrochloride. The concentrate esmolol composition allows a practitioner the flexibility of choosing a bolus volume for direct injection to a patient or, optionally, to use the composition to make a customized, diluted composition of esmolol. Methods of the present invention provide for the reduction of potential adverse health consequences resulting in the improper dosing of prior art concentrate compositions of esmolol. Also, a medical product is provided that includes a concentrate esmolol housed in a container, and a package housing the container and instructions.11-27-2008
20130217773Method and Device for assistance in delivery of medication, and Formulas - This invention is designed for the convenient and reliable delivery of predetermined doses of topical therapeutic medications applied to the skin.08-22-2013
20090149543SOLID PHARMACEUTICAL COMPOSITIONS COMPRISING LUMIRACOXIB - A method of treating a cyclooxygenase-2 dependent disorder or condition comprising administering 5-methyl-2-(2′-chloro-6′-fluoroanilino)phenylacetic acid in an amount effective to treat such a disorder or condition for about 24 hours, comprising administering orally once a day to a human in need of such treatment one or more immediate release pharmaceutical compositions comprising 5-methyl-2-(2′-chloro-6′-fluoroanilino)phenylacetic acid, and compositions suitable for use in such methods.06-11-2009
20080269333ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS - The present invention provides pharmaceutical compositions useful in treating hepatitis C infection. The present invention also provides methods of treating hepatitis C infection by administering to a mammal the pharmaceutical compositions of the present invention.10-30-2008
20090030082SYNTHETIC LIGANDS SELECTIVE FOR LXRbeta OVER LXRalpha, IDENTIFICATION AND METHODS OF USE THEREOF - LXR nuclear receptor agonists have been previously shown to increase cholesterol efflux, raise plasma HDL cholesterol, stimulate cholesterol excretion, and reduce atherosclerotic lesions. However, these agonists have also been associated with the unwanted side effect of hypertriglyeridemia. This hypertriglyeridemia appears to be mediated by the LXRα subtype rather than LXRβ, which suggests that LXRβ-selective agonists are attractive candidates for modulation of human lipid metabolism. The present application provides novel LXRβ-selective ligands that preferably modulate LXRβ over LXRα. These ligands may be used to treat a variety of diseases associated with LXR, such as for example lipid metabolism disorders, atherosclerosis, Alzheimer disease, and inflammation.01-29-2009
20090005451COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS - Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed.01-01-2009
20100204330Diclofenac Formulations and Methods of Use - Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting.08-12-2010
20090197961Diclofenac Formulations and Methods of Use - Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting.08-06-2009
20110144206USE OF A COX-2 INHIBITOR FOR THE TREATMENT OF A COX-2 DEPENDENT DISORDER IN A PATIENT NOT CARRYING HLA ALLELES ASSOCIATED WITH HEPATOTOXICITY - This disclosure relates to a method of determining the presence of at least one HLA allele, preferably selected from the group consisting of DQA1*0102, DRB1*1501, DQB1*0602 and DRB5*0101 to assess whether a patient is at risk for developing hepatotoxicity upon administration of the COX-2 inhibitor lumiracoxib. Also disclosed is the use of a kit for carrying out this method. The disclosure also relates to a method of treating cyclooxygenase-2 dependent disorders with lumiracoxib in a subject that is not a carrier of one or more HLA alleles, preferably selected from the group consisting of DQA1*0102, DRB1*1501, DQB1*0602 and DRB5*0101.06-16-2011
20090082451USE OF THYROID HORMONE CONVERSION INHIBITORS - The present invention is directed to the use of thyroid hormone conversion inhibitors to treat hyperproliferative skin disorders, preferably their use in topical admixtures.03-26-2009
20100197791PHARMACEUTICALS FOR TRANSDERMAL USE ON ANIMALS - The invention relates to pharmaceutical preparations for use on animals, which are applied to the fur or the skin of the animal and whose active ingredient subsequently undergoes transdermal absorption.08-05-2010
20090048344Pharmaceutical composition comprising 5-methyl-2-2' (chloro-6'-fluoroanilino phe nylacetic acid - Provided are compositions comprising aqueous suspensions of 5-methyl-2-(2′-chloro-6′-fluoroanilino)phenylacetic acid suitable for oral administration. Methods for making such compositions and methods for their stabilization are provided.02-19-2009
20090048343Compounds and Their Salts Specific to the PPAR Receptors and the EGF Receptors and Their Use in the Medical Field - The present invention relates to compounds comprising the general formula (I), in which R02-19-2009
20130190402Methods Of Treating Autism With mGluR5 Antagonists - mGluR5 antagonists are used for the treatment of autism. The human treated by the methods of the invention can also have fragile X syndrome, epilepsy and anxiety.07-25-2013
20100197788Preventive or therapeutic agent for disease caused by decrease in lacrimal fluid - The present invention provides pharmaceuticals for the prevention or treatment of diseases associated with decrease in tear. That is, the present invention provides pharmaceuticals for the prevention or treatment of diseases associated with decrease in tear such as dry eye, dry disorders of cornea and conjunctiva, disorders of the keratoconjunctival epithelium, syndrome with decrease in tear secretion, xerophthalmia, dry eye due to aging, opthalmopathy in Stevens-Johnson syndrome, opthalmopathy in Sjögren's syndrome, keratoconjunctival ulcer, dryness in wearing of contact lens or the like, which comprises a β08-05-2010
20100197789ANTI-OBESITY AGENT AND USE THEREOF - Disclosed is a novel anti-obesity agent. Also disclosed is a therapeutic method using the anti-obesity agent. The anti-obesity agent comprises a GABA08-05-2010
20110237674TOPICAL NSAID COMPOSITIONS HAVING SENSATE COMPONENT - Topical pharmaceutical compositions comprising a topically administrable NSAID, a sensate agent and optionally a self-warming system, when administered to a patient in need thereof, provide significant improvements in the rate and extent of skin absorption, as well as impart a sensation of rapid and complete relief from pain.09-29-2011
20100227927SALTS OF TRAMADOL AND NAPROXEN AND THEIR CRYSTAL FORMS IN THE TREATMENT OF PAIN - The present invention concerns salts of Tramadol and Naproxen and their crystalline forms, and compositions thereof, for the treatment of pain, as well as their process for preparation.09-09-2010
20100240757SYSTEMS AND METHODS FOR DELIVERING A FLUID DRUG - Devices and methods for distributing a fluid, e.g., a fluid drug, are disclosed. Fluid-drug distribution can be advantageously utilized to help patients suffering from a disorder that affect fine motor skill usage, e.g., Parkinson's Disease. Some aspects are directed to dosing containers that are adapted to distribute one or more selected dosages of fluid from the container. In some instances, the containers are adapted to be operable by patients with hindered fingertip motor control to help dispense a fluid-drug, such as a fluid including carbidopa and levodopa. Other aspects are directed to a kit for distributing a fluid drug that can be stored with a longer shelf life in solid form. Also discussed herein are methods for distributing a fluid drug for treating a disorder such as Parkinson's Disease.09-23-2010
20100144882Method of Treating Post-Surgical Acute Pain - A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than or equal to about 100 mg. The method is particularly useful in treating acute pain in bunionectomy patients.06-10-2010
20090076150DEUTERIUM-ENRICHED BROMFENAC - The present application describes deuterium-enriched bromfenac, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-19-2009
20100222430Method of Treating Post-Surgical Acute Pain - A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than or equal to about 100 mg. The method is particularly useful in treating acute pain in bunionectomy patients.09-02-2010
20120142779STABLE INJECTABLE COMPOSITIONS - This invention relates to a stable parenteral aqueous solutions comprising either (a) diclofenac or a pharmaceutically acceptable diclofenac salt and a cyclodextrin, or (b) an inclusion complex of diclofenac or a pharmaceutically acceptable diclofenac salt and a cyclodextrin, or a mixture of (a) and (b), which are suitable for intramuscular and intravenous administration. The solutions contain diclofenac or diclofenac salt, cyclodextrin, and an antioxidant selected from monothioglycerol, or a combination of ethylene diamine tetra-acetic acid and N-acetyl-cysteine.06-07-2012
20100035993METHODS AND COMPOSITIONS COMPRISING 2-[(3-CHLOROPHENYL) AMINO] PHENYLACETIC ACID FOR HYPERPERMEABILITY AND NEOVASCULARIZATION DISORDERS OF THE RETINA - Method of preventing or arresting the progression of hyperpermeability and neovascularization of the retina by administering to a patient at risk for retinal microvascular disease a composition comprising a compound or pharmaceutically acceptable salt thereof that lowers the ocular ratio of VEGF to PEDF.02-11-2010
20090163593AMINES THAT INHIBIT A MAMMALIAN ANANDAMIDE TRANSPORTER, AND METHODS OF USE THEREOF - One aspect of the present invention relates to amines. A second aspect of the present invention relates to the use of the amines as inhibitors of a mammalian anandamide transporter. The compounds of the present invention will also find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to asthma, neuropathic pain, persistent pain, inflammatory pain, hyperactivity, hypertension, brain ischemia, Parkinson's disease, spasticity, Tourette's syndrome, schizophrenia, hemorrhagic shock, septic shock, cardiac shock, migrane, Horton's headache, multiple sclerosis, anorexia, AIDS wasting syndrome, organ rejection, autoimmune diseases, allergy, arthritis, Crohn's disease, malignant gliomas, neurodegenerative diseases, Huntington's chorea, glaucoma, nausea, anxiety, psychosis, attention deficit hyperactivity disorder, premature ejaculation, and stroke. Another aspect of the present invention relates to combinatorial libraries of amines, and methods for preparing the libraries.06-25-2009
20100298438GENE EXPRESSION PROFILING OF PARKINSON'S DISEASE - The present invention identifies the changes in gene expression associated with Parkinson's Disease by examining multiregional gene expression from normal brain and brain of Parkinson's Disease. The present also identifies the changes in gene expression associated with Parkinson's Disease by examining the expression of genes from normal blood and from the blood of patients with Parkinson's Disease. In another aspect, the present invention identifies expression profiles which serve as useful diagnostic markers as well as markers that can be used to monitor disease states, disease progression, drug toxicity, drug efficacy and drug metabolism.11-25-2010
20100324141HIGH PURITY 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES AND METHODS OF USE THEREOF - A process for obtaining therapeutically active 2-[4-(3- and 2-(fluorobenzyloxy)benzylamino]-propanamides and their salts with pharmaceutically acceptable acids with a high degree of purity, i.e. with a content of dibenzyl derivatives impurities lower than 0.03% by weight. The process is carried out by submitting a Schiff base intermediate to a reduction reaction with a reducing agent in an amount of organic solvent to allow the formation (and presence during a substantial portion of the reduction reaction) of a suspension of the Schiff base.12-23-2010
20100179221FLUORINE-SUBSTITUTED AMPHETAMINES AND AMPHETAMINE DERIVATIVES AND USE THEREOF - A fluorine-substituted amphetamine or amphetamine derivative with the formula (I):07-15-2010
20090076151METHOD FOR STIMULATING WEIGHT LOSS AND/OR FOR LOWERING TRIGLYCERIDES IN PATIENTS - Administration of a therapeutically effective amount of 3,5-diiodothyropropionic acid stimulates weight loss in patients, lowers triglyceride levels and reduces risk of death or progression of coronary heart disease in patients with metabolic syndrome.03-19-2009
20110118353METHOD OF HORMONE SUPPRESSION IN HUMANS - The present invention relates to a glycine transporter-1 inhibitor having the formula (I) wherein X is 1-3 substituents selected from H, halogen, methyl, methoxy, trifluoromethyl and trifluoromethoxy and Y is 1-3 substituents selected from H, methyl and halogen or a pharmaceutically acceptable salt thereof for use in a treatment in humans to suppress the level of one or more hormone selected from luteinizing hormone, follicle-stimulating hormone, estradiol and testosterone. The present invention further relates to such a glycine transporter-1 inhibitor as part of a contraceptive regimen or as a treatment for hypersexuality.05-19-2011
20090247638PHARMACEUTICAL USE OF COX-2-INHIBITORS IN ANGIOGENESIS-MEDIATED OCULAR DISORDERS - The invention provides a method of treating an angiogenesis-mediated ocular disorder, e.g. ocular neovascularisation, retinal neovascularisation, including neovascularisation following injury or infection, retrolental fibroplasias, and neovascular glaucoma, age-related macular degeneration, diabetic retinopathy, pathologic myopia, ocular histoplasmosis, neovascular glaucoma, retinopathy of prematurity, the after effects of corneal transplantation, control of postsurgical ocular inflammation (e.g. after cataract surgery), cystoid macular edema (CME), herpes keratitis, in a subject in need of such treatment which comprises administering to the subject an effective amount of a COX-2 inhibitor of formula I10-01-2009
20110092597METHOD FOR TREATING HERPES VIRUS INFECTION - The present invention is directed to a method for inhibiting herpes viral activity in a subject, by administering to the subject in need thereof an active ingredient consisting essentially of an effective amount of diclofenac (for example, 3-7% w/v) or a pharmaceutically acceptable salt thereof.04-21-2011
20100069494LOWERING OF PROTEINS ASSOCIATED WITH ALZHEIMER'S DISEASE BY INTERRUPTING GENE TRANSCRIPTION WITH A SMALL MOLECULE - A method of treating Alzheimer's disease in a patient. The method includes administrating tolfenamic acid to the patient to modulate precursors of pothgene intermediates. The treatment also lowers SP1, APP and Aβ1 levels.03-18-2010
20100016436Transdermal Administration of Active Agents, in Particular Diclofenac - The present invention relates to compositions for transdermal administration of therapeutic agents for providing a local and sustained therapeutic effect, wherein the extent of systemic administration can be controlled. In particular, the invention relates to spreadable compositions, or compositions which may be solid at a temperature of about 25° C. or less and have a softening point of not higher than 35° C., for use in the treatment of pain and/or inflammation or administration of a local anaesthetic, wherein transdermal administration of the therapeutic agent may be either rapid or sustained.01-21-2010
20080249176Methods and Compositions for the Treatment of Myocardial Conditions - The present invention relates to methods for the treatment of conditions characterised by abnormalities of myocardial cell ion levels, such as Na10-09-2008
20110054031Ophthalmic NSAIDS as Adjuvants - The disclosure provides methods and ophthalmic NSAIDs as adjuvants to VEGF inhibitors useful for treating retinal disorders, including but not limited to wet AMD, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, and branch retinal vein occlusion.03-03-2011
20100168239Use of Rasagiline for the Treatment of Multiple System Atrophy - Disclosed is a method for the treatment of Multiple System Atrophy comprising administering to a subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.07-01-2010
20110178178Treatment of Motor Fluctuations - The invention relates to the use of compounds that enhance 5-hydroxytryptamine 1a receptor activity, or activation (e.g. a selective 5-hydroxytryptamine 1a receptor agonists) for preventing or reducing motor fluctuations associated with dopamine replacement therapy.07-21-2011
20100197790CONTAINER FOR PHARMACEUTICAL USE FOR THE QUANTITATIVE RELEASE OF A SINGLE DOSE FOR ORAL ADMINISTRATION OF T3 AND T4 THYROID HORMONES IN SOLUTION - The present disclosure relates to a container for pharmaceutical use for the quantitative release of a single-dose for oral administration of the T3 and T4 thyroid hormones in solution, characterized by the fact of being formed with a plastic material having a Young's modulus between 10 and 80 MPa.08-05-2010
20100029771TREATMENT OF ADDICTIVE DISORDERS - The present invention is directed to the treatment of addiction, and particularly to addictions with a chemical dependency component, with gamma-hydroxybutyrate (GHB) and at least one gamma-aminobutyric acid (B) receptor agonist (GABA02-04-2010
20100029769TOPICAL FORMULATION - There is described a topical formulation. The topical formulation comprises: (i) diclofenac or a pharmaceutically acceptable salt thereof, (ii) a first compound, and (iii) a second compound. The first compound and second compound are different, and each is selected from the group consisting essentially of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate and sodium lauryl sulfoacetate. It has been discovered that certain combination of compounds are excellent penetration enhancers and, as such, can be incorporated in a topical formulation to facilitate administration of diclofenac or a pharmaceutically acceptable salt thereof. The increased penetration enhancement can also lead to a reduction in the total concentration of skin irritants in the formulation.02-04-2010
20110218247FORMULATIONS OF LOW DOSE DICLOFENAC AND BETA-CYCLODEXTRIN - The present invention is directed to a pharmaceutical composition containing a unit dose of a diclofenac compound effective to induce analgesia; and a beta-cyclodextrin compound; wherein the dose of the diclofenac compound is less than 10 mg. The present invention is also directed to methods of treating a subject in need of analgesia with the pharmaceutical compositions of the invention.09-08-2011
20100016437ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS - The present invention is in the field of pharmacotherapy of cognitive deficits in learning and memory by administering an α-aminoamide, particularly safinamide. Examples of disturbances in cognition that can be treated with compounds of the invention are the ones associated with disorders such as autism, dyslexia, attention deficit hyperactivity disorder, schizophrenia, obsessive compulsive disorders, psychosis, bipolar disorders, depression, Tourette's syndrome, Mild Cognitive Impairment (MCI) and disorders of learning in children, adolescents and adults, Age Associated Memory Impairment, Age Associated Cognitive Decline, Alzheimer's Disease, Parkinson's Disease, Down's Syndrome, traumatic brain injury Huntington's Disease, Progressive Supranuclear Palsy (PSP), HIV, stroke, vascular diseases, Pick's or Creutzfeldt-Jacob diseases, multiple sclerosis (MS), other white matter disorders and drug-induced cognitive worsening.01-21-2010
20100120918NOVEL NON-AQUEOUS TOPICAL SOLUTION OF DICLOFENAC AND PROCESS FOR PREPARING THE SAME - A non-aqueous topical solution composition of pharmaceutically acceptable salt of diclofenac is disclosed. The non-aqueous topical solution composition comprises therapeutically effective amount of pharmaceutically acceptable salt of diclofenac, solublizer, penetration enhancer and solvent, and optionally a humectant, counter irritant, additional penetration enhancer and anti-oxidants and a process for preparing the same.05-13-2010
20090170948Crystal forms of O-desmethylvenlafaxine fumarate - Provided are crystalline forms of O-desmethylvenlafaxine fumarate, methods for their preparation, and pharmaceutical compositions thereof.07-02-2009
20100069493AQUEOUS PHARMACEUTICAL FORMULATION OF 4-[((4-CARBOXYBUTYL)-AMINO)METHYL]BENZOIC ACID - The present invention relates to an aqueous pharmaceutical formulation which comprises 4-[((4-carboxybutyl)-{2-[(4-phenethylbenzyl)oxy]phenethyl}amino)methyl]benzoic acid or a salt thereof. The present invention relates in particular to an aqueous pharmaceutical formulation which comprises 4-[((4-carboxybutyl)-{2-[(4-phenethylbenzyl)oxy]phenethyl}amino)methyl]benzoic acid and 2-amino-2-(hydroxymethyl)-1,3-propanediol (trometamol).03-18-2010
20100216887INTRATHECAL BACLOFEN PHARMACEUTICAL DOSAGE FORMS WITH FEWER DEGRADATION PRODUCTS - The present invention relates generally to a sterile, particulate-free, stable intrathecal baclofen solution with less than 0.5% 4-(4-chlorophenyl)-2-pyrrolidone, a degradation product. These solutions are stable under a variety of storage conditions and for extended periods of time. Also disclosed are methods for preparing such compositions.08-26-2010
20100305208GASTRIC RETENTION CONTROLLED DRUG DELIVERY SYSTEM - The present invention provides a gastric retention controlled drug delivery system comprising: 12-02-2010
20110028555Antiinflammatory and Analgesic Preparation for External Use - It is intended to provide an antiinflammatory and analgesic preparation for external use whereby side effects of a nonsteroidal antiinflammatory and analgesic drug on the skin can be regulated, the nonsteroidal antiinflammatory and analgesic drug can be prevented from degeneration with time due to a dibenzoylmethane derivative contained as an UV absorbent therein, the dibenzoylmethane derivative can be prevented from crystallization and sedimentation due to an oily phase component contained therein, and the inherent effects of the nonsteroidal anti-inflammatory and analgesic drug can be fully exerted without showing skin irritation caused by the oily phase component, an emulsifier and a thickener. The above problem can be solved by providing an antiinflammatory and analgesic preparation for external use which comprises a base for external use containing an oily phase component, a nonsteroidal antiinflammatory and analgesic drug and a dibenzoylmethane derivative and in which the total amount of fatty acid esters in the oily phase component is at least thrice as much as the content of the dibenzoylmethane derivative.02-03-2011
20120004306EXTERNAL PREPARATION CONTAINING ANALGESIC/ANTI-INFLAMMATORY AGENT - An external preparation containing the following components (A), (B), and (C): 01-05-2012
20120208886Moisture Resistant Container Systems for Rapidly Bioavailable Dosage Forms - Provided are rapidly bioavailable solid oral dosage forms of acute pain medications, and moisture resistant packaging that enables the formulation of such rapidly bioavailable dosage forms.08-16-2012
20120065268High Concentration Baclofen Preparations - Stable aqueous solutions comprising concentrations of baclofen in the range of greater than 2.0 mg/mL up to about 10 mg/mL are disclosed. These solutions can be used as pharmaceuticals for parenteral or oral administration. The invention also provides methods of preparing said stable aqueous baclofen solutions.03-15-2012
20120065267COMPOSITIONS INCLUDING 3,5-L-T2 AND METHODS OF USE THEREOF - Compositions containing 3,5-L-T2 ((2S)-2-amino-3-[4-(4-hydroxyphenoxy)-3,5-diiodophenyl]propanoic acid) and methods for use thereof. Among other functions presented herein, 3,5-L-T2 can lower cholesterol via a mechanism that is independent of LDL receptor function. Disclosed compositions may include one or more additional active agents, such as, but not limited to, thyroid hormones other than 3,5-L-T2, cholesterol lowering agents, anti-diabetes agents, anti-hypertensives, vasodilators, inotropic agents, anti-coagulants, anti-anginals, anti-arrhythmics, leptin, leptin analogues, and adipokines, a vitamin and mineral composition. Disclosed methods include, but are not limited to, methods for treating hypercholesterolemia in a subject, and methods for treating at least one of metabolic syndrome, hypothyroidism, or thyroid suppression.03-15-2012
20120010293DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF MOOD DISORDERS, SLEEP DISORDERS, OR ATTENTION DEFICIT DISORDERS - The present invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active ingredients, for the treatment of conditions, such as mood disorders, sleep disorders, or attention deficit disorders. In certain embodiments, the compositions useful in the methods of the invention comprise droxidopa and a compound selected from the group consisting of DOPA decarboxylase inhibiting compounds, catechol-O-methyltransferase inhibiting compounds, cholinesterase inhibiting compounds, monoamine oxidase inhibiting compounds, norepinephrine reuptake inhibiting compounds, selective serotonin reuptake inhibiting compounds, tricyclic antidepressant compounds, serotonin norepinephrine reuptake inhibiting compounds, norepinephrine dopamine reuptake inhibiting compound, noradrenergic and specific serotonergic antidepressants, and combinations thereof. The inventive compositions are particularly useful in the treatment of depression, narcolepsy, insomnia, and Attention Deficit/Hyperactivity Disorder (AD/HD).01-12-2012
20120010292MODIFICATION I OF 4-(PHENYL)ETHYL]-AMINO}METHYL)BENZOIC ACID - The invention relates to novel forms of 4-({(4-carboxybutyl)[2-(2-{[4-(2-phenyl-ethyl)benzyl]oxy}phenyl)ethyl]amino}methyl)benzoic acid, in particular to the modification I, to processes for their preparation, to medicaments comprising them and to their use for fighting diseases.01-12-2012
20120115957AQUEOUS LIQUID PREPARATION CONTAINING 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID - An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).05-10-2012
20120157536COMPOSITION FOR TRANSDERMAL ADMINISTRATION OF NON-STEROIDAL ANTI-FLAMMATORY DRUG - This invention pertains to compositions and method for transdermal administration of non-steroidal anti-inflammatory and analgesic drugs (NSAID) for the treatment of inflammation and pain caused by conditions such as arthritis, degenerative joint disease, minor strains, pains, and contusions. This invention particularly relates to transdermal compositions comprising an NSAID, a bioadhesive graft copolymer, and a skin penetration enhancer, selected from pyrrolidone or its derivatives and dialkyl sulfoxides and combinations thereof.06-21-2012
20110092596POLYMORPHS OF BROMFENAC SODIUM AND METHODS FOR PREPARING BROMFENAC SODIUM POLYMORPHS - Different polymorphs of bromfenac sodium may be prepared and interconverted using crystallization/recrystallization, drying and/or hydration techniques.04-21-2011
20110092595Compositions and Methods for Treating Lung Cancer - Embodiments of the present invention provide compositions and methods for treating lung cancer, including small cell and non-small cell lung cancer that may express HIF-1a by administering a therapeutically effective amount of PX-478.04-21-2011
20110105615TABLET QUICKLY DISINTEGRATING IN THE ORAL CAVITY AND METHOD FOR PRODUCING THE SAME - The present invention relates to a tablet which is rapidly disintegrated in an oral cavity containing an active ingredient at a high content and a production method thereof. That is, the present invention provides a tablet which is rapidly disintegrated in an oral cavity containing an active ingredient in not less than 25% of the total weight, having a disintegration time of within 40 seconds and an absolute hardness of 1.8 N/mm05-05-2011
20110105614High Concentration Baclofen Preparations - Stable aqueous solutions comprising concentrations of baclofen in the range of greater than 2.0 mg/mL up to about 10 mg/mL are disclosed. These solutions can be used as pharmaceuticals for parenteral or oral administration. The invention also provides methods of preparing said stable aqueous baclofen solutions.05-05-2011
20110105613MOISTURE RESISTANT CONTAINER SYSTEMS FOR RAPIDLY BIOAVAILABLE DOSAGE FORMS - Provided are rapidly bioavailable solid oral dosage forms of acute pain medications, and moisture resistant packaging that enables the formulation of such rapidly bioavailable dosage forms.05-05-2011
20120122986Methods of Treating Fragile X Syndrome - Subjects having fragile X syndrome are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen, including racemic and R-baclofen.05-17-2012
20090131527NOVEL ANTHRANILIC ACID DERIVATIVES AND CHLORIDE CHANNEL BLOCKING AGENT CONTAINING THE SAME - The present invention relates to novel anthranilic acid derivatives represented by Chemical Formula I, and a chloride channel blocking agent containing the anthranilic acid derivative or its pharmacologically acceptable salts as an active ingredient. In another aspect, the present invention relates to a method of accurately and efficiently detecting the intracellular chloride channel inhibition and method of screening a chloride channel blocking agent.05-21-2009
20120165409WRINKLE-IMPROVING AGENT - A wrinkle-improving agent that has an effect of improving wrinkles, that does not entail problems of safety or pain even when applied to the skin, and that contains a very safe substance as an active component. A discovery was made that N-benzoyl-β-alanine, other specific β-alanine derivatives, and salts thereof have a wrinkle-improving effect, whereby a wrinkle-improving agent containing as an active component one, two, or more types of compounds selected from the group composed of these specific β-alanine derivatives and the salts thereof was developed.06-28-2012
20120129940METHODS OF TREATING AUTISM - Subjects having autism are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen.05-24-2012
20080300311DICLOFENAC GEL - The present invention provides a gel formulation comprising diclofenac sodium which has superior transdermal flux properties, which may be used for the topical treatment of pain, such as in osteoarthritis.12-04-2008
20080300310Methods of administering diclofenac compositions for treating photodamaged skin, rosacea and/or acne - A method of treating at least one dermatological disorder selected from the group consisting of photodamage-induced wrinkles, rosacea, and acne, includes: (a) providing a composition containing 1-3 wt. % diclofenac or a salt thereof, 0.5-1.5 wt. % benzyl alcohol, 10-30 wt. % PEG monomethyl ether, 0.1-3.0 wt. % sodium hyaluronate; and 70-80 wt. % water; and (b) applying the composition to skin of a person in need of the treating in an amount effective to treat the at least one dermatological disorder.12-04-2008
20110028554 PHARMACEUTICAL COMPOSITIONS COMPRISING DIIODOTHYRONINE AND THEIR THERAPEUTIC USE - The present invention relates to a pharmaceutical composition comprising, as active substance, at least one hormone chosen among 3,5-diiodothyronine (3,5-T2), 3′,3-diiodothyronine (3′,3-T2), 3′,5-diiodothyronine (3′,5-T2), 3′-iodothyronine (3′-T), 3-iodothyronine (3-T) or 5-iodothyronine (5-T), in association with a pharmaceutically acceptable vehicle.02-03-2011
20120322874Pharmaceutical Uses - The invention provides a method of treating an angiogenesis-mediated ocular disorder, e.g. ocular neovascularisation, retinal neovascularisation, including neovascularisation following injury or infection, retrolental fibroplasias, and neovascular glaucoma, age-related macular degeneration, diabetic retinopathy, pathologic myopia, ocular histoplasmosis, neovascular glaucoma, retinopathy of prematurity, the after effects of corneal transplantation, control of postsurgical ocular inflammation (e.g. after cataract surgery), cystoid macular edema (CME), herpes keratitis, in a subject in need of such treatment which comprises administering to the subject an effective amount of a COX-2 inhibitor of formula I12-20-2012
20100249233COMPOUND AND USE THEREOF IN THE TREATMENT OF AMYLOIDOSIS - The present invention relates to compounds of formula (I) for stabilizing the tetrameric form of transthyretin, compounds for use in the treatment or prevention of amyloidosis, and agents and medicaments comprising such compounds.09-30-2010
20100234462TOPICAL COMPOSITION - The invention relates to beneficial topical pharmaceutical compositions comprising diclofenac sodium salt in unusually low amounts. The compositions represent opaque emulsion-gels, in which diclofenac is kept fully dissolved.09-16-2010
20110319490METHODS AND COMPOSITIONS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME - A method for a prevention and/or treatment of irritable bowel syndrome or amelioration of a symptom thereof in a subject, comprises administering to said subject an effective amount of a compound of formula I:12-29-2011
20120101164ABSCISSION AND CROP STORAGE UNIT - A composition comprising a compound selected from an auxin, an auxin precursor, an auxin metabolite or a derivative of said auxin, auxin precursor or auxin metabolite or a mixture thereof and optionally acetaminophen or a derivative thereof for improving post-harvest storability of crops.04-26-2012
20130012586Methods of Treating Fragile X Syndrome - Subjects having fragile X syndrome are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen, including racemic and R-baclofen.01-10-2013
20130012585Phenylacetic Acid Derivatives - Compounds of formula (I) pharmaceutically acceptable salts thereof; and pharmaceutically acceptable esters thereof; which are useful for the treatment of COX-2 dependent disorders.01-10-2013
20130012587Methods of Treating Autism - Subjects having autism are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen.01-10-2013
20100160437TOPICAL COMPOSITION COMPRISING A CYCLOFRUCTAN, A CARRIER AND A DRUG - The present invention relates in particular to a drug delivery system comprising a cyclofructan, a drug and a polymeric carrier.06-24-2010
20100130612COMPOSITION CONTAINING CHITOSAN FOR SUSTAINED DRUG RELEASE - The present invention relates to a composition for sustained drug release, comprising chitosan dissolved in a solvent having a pH of below about 4.0, wherein the chitosan is selected from the group of chitosans precipitating in a pH range of between about 3.0 and about 7.5; and at least one drug compound soluble in the above chitosan solution.05-27-2010
20130023588POLYMORPHS OF BROMFENAC SODIUM AND METHODS FOR PREPARING BROMFENAC SODIUM POLYMORPHS - Different polymorphs of bromfenac sodium may be prepared and interconverted using crystallization/recrystallization, drying and/or hydration techniques.01-24-2013
20080255236Methods and Composition Comprising 2-[(3-Chlorophenyl)Amino] Phenylacetic Acid for Alzheimer's Disease - The present invention is directed to a method of preventing or arresting the progression of Alzheimer's disease by administering to a patient having Alzheimer's disease a composition comprising an amount of 2-[(3-chlorophenyl)amino]phenylacetic acid, or a pharmaceutically acceptable salt thereof, sufficient to elicit a prophylactic or therapeutic effect. In some embodiments, the composition is administered orally, transdermally, intravenously, intrathecally, or by suppository. In some embodiments, the composition comprises a pharmaceutically acceptable carrier.10-16-2008
20080255235Infusion and Injection Solution of Levodopa - An infusion or injection solution of Levodopa containing at least 10 mg/mL of Levodopa, or at least 5 mg/mL of Levodopa together with at least 0.5 mg/mL of at least one inhibitor of a Levodopa-metabolising enzyme is disclosed. The solution further contains a buffer, a physiologically acceptable sugar, such as glucose, a physiologically acceptable acid, such as hydrochloric acid, and optionally a stabilizer, and has a pH of lower than or equal to 6. There are also described a disposable syringe containing an infusion or injection solution of Levodopa, optionally together with a Levodopa-metabolising enzyme, and an infusion pump cassette containing an infusion or injection solution of Levodopa optionally together with a Levodopa-metabolising enzyme.10-16-2008
20080249177AMINO ALCOHOL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND USE THEREOF - The present invention provides compounds represented by general formula (I):10-09-2008
20090326072USE OF 2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-l,3- CYCLOHEXANEDIONE IN THE TREATMENT OF PARKINSON'S DISEASE - The present invention relates to, inter alia, the use of 2-(2-Nitro-4-Trifluoromethylbenzoyl)-1,3-Cyclohexanedione (compound 2) in the treatment of a neurodegenerative disease, such as Parkinson's disease. The invention also relates to the use of the compound depicted as compound 2 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of a neurodegenerative disease such as Parkinson's disease.12-31-2009
20080221212TOPICAL FORMULATION - There is described a topical formulation. The topical formulation includes: (i) diclofenac or a pharmaceutically acceptable salt thereof, (ii) a first compound, and (iii) a second compound. The first compound and second compound are different, and each is selected from the group consisting essentially of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate and sodium lauryl sulfoacetate. It has been discovered that certain combination of compounds are excellent penetration enhancers and, as such, can be incorporated in a topical formulation to facilitate administration of diclofenac or a pharmaceutically acceptable salt thereof. The increased penetration enhancement can also lead to a reduction in the total concentration of skin irritants in the formulation.09-11-2008
20110269836INTRATHECAL BACLOFEN PHARMACEUTICAL DOSAGE FORMS AND RELATED DELIVERY SYSTEM - According to the subject invention, there is disclosed, a dosage and packaging configuration which includes the use of color-coded pre-filled syringes and vials to fill and refill infusion systems with existing and new dosage forms of intrathecal baclofen.11-03-2011
20130096199BROMFENAC BIOAVAILABILITY - Formulations and methods that provided enhanced bromfenac penetration into ocular tissue when topically administered, compared to the currently available BROMDAY™ formulation and method when topically administered. The formulations and methods did so while retaining the patient convenience of a once-daily administration and advantageously lowered the bromfenac concentration dosed to the patient.04-18-2013
20130131176High Concentration Baclofen Preparations - Stable aqueous solutions comprising concentrations of baclofen in the range of greater than 2.0 mg/mL up to about 10 mg/mL are disclosed. These solutions can be used as pharmaceuticals for parenteral or oral administration. The invention also provides methods of preparing said stable aqueous baclofen solutions.05-23-2013
20100286276Substituted 1,3-Diphenylpropane Derivatives, Preparations and Uses Thereof - The present invention concerns substituted 1,3-diphenylpropane derivatives, pharmaceutical compositions comprising them and the therapeutic uses thereof, particularly in the field of human and animal health.11-11-2010
20110275717PHARMACEUTICAL FORMULATION COMPRISING DICLOFENAC - The present invention relates to a pharmaceutical formulation comprising a pharmaceutically acceptable salt of diclofenac, at least one polyoxyalkylene ester of a hydroxy fatty acid, water, and, optionally, a co-solvent.11-10-2011
20100317738COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH NEURONAL DYSFUNCTION - The present invention relates to compositions and methods for the treating and empirically investigating conditions associated with neuronal dysfunction (e.g., chronic pain, epileptic neuronal activity). In particular, the present invention provides compositions and methods for using flufenamic acid in the treatment and empirical investigation of conditions associated with neuronal dysfunction (e.g., chronic pain, epileptic neuronal activity).12-16-2010
20130197089COMPOSITIONS FOR THE TREATMENT OF ACTINIC KERATOSIS - Ibuprofen can be used in the prevention and treatment of actinic keratosis.08-01-2013
20130197090POSTURAL STABILITY AND INCIDENT FUNCTIONS IN PATIENTS - The present invention provides methods and systems for reducing falls in patients that are recurrent fallers. Specifically, the compositions, systems, and methods can relate to Parkinson's disease patients, particularly such patients that are suffering from neurogenic orthostatic hypotension. The compositions, systems, and methods comprise the use of droxidopa, optionally in combination with a further active agent. Administration of droxidopa has been found to reduce the mean number of falls per patient per week, as well as provide improvements in the patient's Hoehn and Yahr rating scale score, which is indicative of improvements in postural stability, and provide improvements in the patient's Unified Parkinson's disease Rating Scale score, which is indicative of improvements in the severity of motor and/or non-motor symptoms of Parkinson's disease.08-01-2013
20130197091USE OF ADRENERGIC BETA-E-RECEPTOR BLOCKERS IN CANCER TREATMENT - A method for treating an cancer disease is disclosed comprising administering to a subject a pharmaceutical composition comprising an adrenergic beta-3-receptor blocker.08-01-2013
20130197092Novel Non-Aqueous Topical Solution of Diclofenac and Process for Preparing the Same - A novel non-aqueous topical solution composition of pharmaceutically acceptable salt of diclofenac is disclosed. The non-aqueous topical solution composition comprises therapeutically effective amount of pharmaceutically acceptable salt of diclofenac, solublizer, penetration enhancer and solvent, and optionally a humectant, counter irritant, additional penetration enhancer and anti-oxidants and a process for preparing the same.08-01-2013
20120295978DICLOFENAC GEL - The present invention provides a gel formulation comprising diclofenac sodium which has superior transdermal flux properties, which may be used for the topical treatment of pain, such as in osteoarthritis.11-22-2012
20120095101AQUEOUS INTRAOCULAR PENETRATION-PROMOTING EYE DROP - An aqueous eye drop comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof and an organic amine (for example, aminoethylsulfonic acid or trometamol) or a salt thereof is useful as an eye drop for once a day administration for treating inflammatory diseases of the external segment or the anterior segment of the eyes, since such aqueous eye drop can maintain a therapeutically effective concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid in anterior aqueous humor for at least 24 hours by once a day administration.04-19-2012

Patent applications in class Benzene ring nonionically bonded